New Rhein applies a private equity business model to life sciences venture capital investing, focusing on assets with proven clinical safety and efficacy applied in new ways (i.e. new delivery forms, new indications). Our goal is to develop products that deliver compelling health benefits to patients and compelling economic value to payors.
New Rhein combines significant deal-making expertise with deep operating experience. We take a significant stake in a small number of companies and actively manages their value creation. In this way, New Rhein's investment strategy limits science-based risk and concentrates on successful development and execution of product development and commercialization.
Prior investments have included medicines or medical devices for Alzheimer’s disease, ophthalmic disorders, respiratory disease, critical care, urology, and oncology.
Our managing partners, advisors, and executives in residence are current and former senior executives of world-renowned pharmaceutical or medical device companies who bring, industry-specific, R&D, operational, transactional, commercialization, and M&A expertise to each deal. Their expertise drives our deal-sourcing, due diligence, and management decisions allowing us to tailor the right plan for each opportunity and sustainably scale businesses to deliver value to patients, payors, strategic acquirers, and our investors.
New Rhein's managing partners have complementary backgrounds in R&D, Commercialization, and M&A. With over 65 years of combined industry experience our team is uniquely positioned to find the right products, bring them to market and drive exits that benefit our investors.
New Rhein Fund 18 has invested in five companies across North America, Europe, and Israel. Prior investments have included medicines for Alzheimer’s disease, ophthalmic disorders, respiratory disease, and molecular oncology diagnostics.